The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors

Clinical Immunology

Volumn 141, Issue 3, 2011, Pages 338-347

  Hamanishi, Junzo ^a   Mandai, Masaki ^a   Abiko, Kaoru ^a   Matsumura, Noriomi ^a   Baba, Tsukasa ^a   Yoshioka, Yumiko ^a   Kosaka, Kenzo ^a   Konishi, Ikuo ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Ovarian cancer; ; Tumor immune escape; Tumor immunity;

Indexed keywords

CD1 ANTIGEN; CD4 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; IMMUNOLOGIC FACTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CLUSTER ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR IMMUNITY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 81355160439     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.08.013     Document Type: Article

References (42)

1. Nelson B.H. The impact of T-cell immunity on ovarian cancer outcomes. Immunol. Rev. 2008, 222:101-116.
2. Liu B., Nash J., Runowicz C., Swede H., Stevens R., Li Z. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J. Hematol. Oncol. 2010, 3:7.
3. Yigit R., Massuger L.F., Figdor C.G., Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol. Oncol. 2010, 117:366-372.
4. Croci D.O., Zacarias Fluck M.F., Rico M.J., Matar P., Rabinovich G.A., Scharovsky O.G. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol. Immunother. 2007, 56:1687-1700.
5. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 10:909-915.
6. Kim R., Emi M., Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007, 121:1-14.
7. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoue F., Bruneval P., Cugnenc P.H., Trajanoski Z., Fridman W.H., Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
8. Sheu B.C., Kuo W.H., Chen R.J., Huang S.C., Chang K.J., Chow S.N. Clinical significance of tumor-infiltrating lymphocytes in neoplastic progression and lymph node metastasis of human breast cancer. Breast 2008, 17:604-610.
9. Ishigami S., Natsugoe S., Tokuda K., Nakajo A., Che X., Iwashige H., Aridome K., Hokita S., Aikou T. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000, 88:577-583.
10. Takeuchi H., Maehara Y., Tokunaga E., Koga T., Kakeji Y., Sugimachi K. Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am. J. Gastroenterol. 2001, 96:574-578.
11. Villegas F.R., Coca S., Villarrubia V.G., Jimenez R., Chillon M.J., Jareno J., Zuil M., Callol L. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002, 35:23-28.
12. Al-Shibli K.I., Donnem T., Al-Saad S., Persson M., Bremnes R.M., Busund L.T. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin. Cancer Res. 2008, 14:5220-5227.
13. Gao Q., Qiu S.J., Fan J., Zhou J., Wang X.Y., Xiao Y.S., Xu Y., Li Y.W., Tang Z.Y. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 2007, 25:2586-2593.
14. Ding T., Xu J., Wang F., Shi M., Zhang Y., Li S.P., Zheng L. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum. Pathol. 2009, 40:381-389.
15. Ladanyi A., Kiss J., Somlai B., Gilde K., Fejos Z., Mohos A., Gaudi I., Timar J. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol. Immunother. 2007, 56:1459-1469.
16. Schleypen J.S., Baur N., Kammerer R., Nelson P.J., Rohrmann K., Grone E.F., Hohenfellner M., Haferkamp A., Pohla H., Schendel D.J., Falk C.S., Noessner E. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin. Cancer Res. 2006, 12:718-725.
17. Piersma S.J., Jordanova E.S., van Poelgeest M.I., Kwappenberg K.M., van der Hulst J.M., Drijfhout J.W., Melief C.J., Kenter G.G., Fleuren G.J., Offringa R., van der Burg S.H. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007, 67:354-361.
18. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C., Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348:203-213.
19. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A.A., Frosina D., Gnjatic S., Ambrosone C., Kepner J., Odunsi T., Ritter G., Lele S., Chen Y.T., Ohtani H., Old L.J., Odunsi K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18538-18543.
20. Hamanishi J., Mandai M., Iwasaki M., Okazaki T., Tanaka Y., Yamaguchi K., Higuchi T., Yagi H., Takakura K., Minato N., Honjo T., Fujii S. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3360-3365.
21. Li K., Mandai M., Hamanishi J., Matsumura N., Suzuki A., Yagi H., Yamaguchi K., Baba T., Fujii S., Konishi I. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol. Immunother. 2009, 58:641-652.
22. Martin F., Ladoire S., Mignot G., Apetoh L., Ghiringhelli F. Human FOXP3 and cancer. Oncogene 2010, 29:4121-4129.
23. Wolf D., Wolf A.M., Rumpold H., Fiegl H., Zeimet A.G., Muller-Holzner E., Deibl M., Gastl G., Gunsilius E., Marth C. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 2005, 11:8326-8331.
24. Garcia-Lora A., Algarra I., Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J. Cell. Physiol. 2003, 195:346-355.
25. Massague J. TGFbeta in cancer. Cell 2008, 134:215-230.
26. Lob S., Konigsrainer A., Rammensee H.G., Opelz G., Terness P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?. Nat. Rev. Cancer 2009, 9:445-452.
27. Thun M.J., Namboodiri M.M., Heath C.W. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 1991, 325:1593-1596.
28. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12293-12297.
29. Okazaki T., Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 2007, 19:813-824.
30. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704.
31. Fong L., Small E.J. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol. 2008, 26:5275-5283.
32. Liu M., Matsumura N., Mandai M., Li K., Yagi H., Baba T., Suzuki A., Hamanishi J., Fukuhara K., Konishi I. Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression. Mod. Pathol. 2009, 22:373-384.
33. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14863-14868.
34. Liu Y.Y., Morreau H., Kievit J., Romijn J.A., Carrasco N., Smit J.W. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur. J. Endocrinol. 2008, 158:375-384.
35. Iida S., Miki Y., Ono K., Akahira J., Suzuki T., Ishida K., Watanabe M., Sasano H. Novel classification based on immunohistochemistry combined with hierarchical clustering analysis in non-functioning neuroendocrine tumor patients. Cancer Sci. 2010, 101:2278-2285.
36. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
37. Stolina M., Sharma S., Lin Y., Dohadwala M., Gardner B., Luo J., Zhu L., Kronenberg M., Miller P.W., Portanova J., Lee J.C., Dubinett S.M. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 2000, 164:361-370.
38. Yang L., Yamagata N., Yadav R., Brandon S., Courtney R.L., Morrow J.D., Shyr Y., Boothby M., Joyce S., Carbone D.P., Breyer R.M. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest. 2003, 111:727-735.
39. Denkert C., Kobel M., Pest S., Koch I., Berger S., Schwabe M., Siegert A., Reles A., Klosterhalfen B., Hauptmann S. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am. J. Pathol. 2002, 160:893-903.
40. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991-998.
41. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., Stankevich E., Pons A., Salay T.M., McMiller T.L., Gilson M.M., Wang C., Selby M., Taube J.M., Anders R., Chen L., Korman A.J., Pardoll D.M., Lowy I., Topalian S.L. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28:3167-3175.
42. Midgley R.S., McConkey C.C., Johnstone E.C., Dunn J.A., Smith J.L., Grumett S.A., Julier P., Iveson C., Yanagisawa Y., Warren B., Langman M.J., Kerr D.J. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J. Clin. Oncol. 2010, 28:4575-4580.